Vertex Pharmaceuticals Incorporated
GPTKB entity
Statements (86)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
gptkb:Company |
| gptkbp:acquisition |
gptkb:Semma_Therapeutics
gptkb:Exonics_Therapeutics |
| gptkbp:awards |
gptkb:Innovative_Medicines_Initiative
Best Places to Work Top Employer Top Employer in Massachusetts 2021 Best Workplaces for Innovators 2022 Fortune 100 Best Companies to Work For |
| gptkbp:ceo |
gptkb:Reshma_Kewalramani
|
| gptkbp:clinical_trial |
ongoing
Phase 3 trials Cell therapies Phase 1 trials Phase 2 trials Small molecule drugs Gene editing therapies Phase 3 trials for CF therapies Protein replacement therapies RNA therapies Therapies for autoimmune diseases Therapies for beta-thalassemia Therapies for cardiovascular diseases Therapies for chronic pain. Therapies for dermatological diseases Therapies for endocrine disorders Therapies for gastrointestinal diseases Therapies for infectious diseases Therapies for metabolic disorders Therapies for neurodegenerative diseases Therapies for ocular diseases Therapies for pain management Therapies for psychiatric disorders Therapies for rare diseases Therapies for respiratory diseases Therapies for sickle cell disease |
| gptkbp:collaboration |
gptkb:Harvard_University
gptkb:Massachusetts_Institute_of_Technology gptkb:University_of_Pennsylvania |
| gptkbp:community_engagement |
education initiatives
research funding local initiatives healthcare access programs |
| gptkbp:employees |
over 3,000
approximately 3,000 |
| gptkbp:focus_area |
gptkb:cystic_fibrosis
|
| gptkbp:founded |
gptkb:1989
|
| gptkbp:founder |
gptkb:Joshua_Boger
|
| gptkbp:global_presence |
international operations
|
| gptkbp:headcount |
3,000+
growing workforce |
| gptkbp:headquarters |
gptkb:Boston,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vertex Pharmaceuticals Incorporated
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:instruction_set |
gptkb:sickle_cell_disease
gptkb:multiple_sclerosis pain management type 1 diabetes |
| gptkbp:investment |
$1 billion in R& D (2022)
|
| gptkbp:leadership |
gptkb:CEO
gptkb:Board_of_Directors |
| gptkbp:market_cap |
$60 billion (2023)
$50 billion (2023) |
| gptkbp:partnership |
gptkb:Astra_Zeneca
gptkb:Moderna gptkb:CRISPR_Therapeutics gptkb:Sarepta_Therapeutics |
| gptkbp:philanthropy |
gptkb:Vertex_Foundation
|
| gptkbp:products |
gptkb:Kalydeco
gptkb:Orkambi gptkb:Symdeko gptkb:Trikafta |
| gptkbp:research_focus |
gptkb:Cystic_Fibrosis
gene editing small molecule drugs |
| gptkbp:revenue |
$6.2 billion (2022)
|
| gptkbp:stock_symbol |
gptkb:VRTX
|
| gptkbp:subsidiary |
gptkb:Vertex_Pharmaceuticals_(Singapore)_Pte._Ltd.
gptkb:Vertex_Pharmaceuticals_(Australia)_Pty_Ltd. gptkb:Vertex_Pharmaceuticals_(Canada)_Inc. Vertex Pharmaceuticals (Europe) Limited. |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.vrtx.com
|
| gptkbp:bfsParent |
gptkb:NASDAQ
|
| gptkbp:bfsLayer |
4
|